Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion.
Transaction reflects the potential of Tourmaline's pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases.
Transaction expected to be completed in the fourth quarter of 2025, subject to customary closing conditions.
Acquisition Agreement
Novartis to acquire Tourmaline Bio for $48.00 per share in cash, totaling approximately $1.4 billion.
Innovative Treatment Potential
Tourmaline's pacibekitug offers a breakthrough in addressing cardiovascular diseases through anti-inflammatory therapies.
Premium Price
Offer represents a premium of 59% to Tourmaline's closing stock price on September 8, 2025.
Board Approval
The transaction has been unanimously approved by the Boards of Directors of both companies.
- Pacibekitug's potential as an anti-inflammatory therapy for cardiovascular diseases aligns with Novartis' focus on innovation in this healthcare sector.
- The acquisition reflects the value and potential recognized in Tourmaline's transformative medicines.
The acquisition by Novartis is set to bring significant value to Tourmaline Bio and further advancements in the treatment of cardiovascular diseases. It marks a new chapter for both companies in addressing unmet medical needs and fostering innovation in healthcare.